BNT162b2 is a lipid nanoparticle鈥揻ormulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. Results A total of 4...
Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577PubMedGoogle ScholarCrossref 10. Baden LR, El Sahly HM, Essink B, et al; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2...
P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020). Article CAS PubMed Google Scholar Voysey, M. et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ...
Safety and Efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15. Article CAS PubMed Google Scholar Etemadifar M, Abhari AP, Nouri H, Sigari AA, Piran Daliyeh SM, Maracy MR et al. Self-reported safety of the BBIBP-CorV (sinopharm) COVID-19 vaccine ...
Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021;385(3):239-250. doi:10.1056/NEJMoa2107456 PubMedGoogle ScholarCrossref 4. Cohen-Stavi CJ, Magen O, Barda N, et al. BNT162b2 vaccine effectiveness against ...
Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents N Engl J Med, 385 (3) (2021), pp. 239-250 CrossrefView in ScopusGoogle Scholar [99] V.-V. Edara, B.A. Pinsky, M.S. Suthar, L. Lai, M.E. Davis-Gardner, K. Floyd, M.W. Flowers, J. Wra...
J. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 Months. N. Engl. J. Med. 385, 1761–1773 (2021). Article CAS PubMed Google Scholar Fischerii, W. A. et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated ...
Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine N Engl J Med, 383 (2020), pp. 2603-2615 CrossrefView in ScopusGoogle Scholar 27 M Voysey, SAC Clemens, SA Madhi, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis...
Since COVID-19 risk of reinfection is of great concern, the safety and efficacy of the mRNA-based vaccines in previously infected populations should be assessed. We studied 78 individuals previously infected with SARS-CoV-19, who received a single dose of BNT162b2 mRNA COVID-19 vaccine, and...
Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents. N Engl J Med. 2021;385(3):239-250. doi:10.1056/NEJMoa2107456 PubMedGoogle ScholarCrossref 27. Ali K, Berman G, Zhou H, et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in ...